Dr. Gitte Neubauer awarded first prize for the foundation of Cellzome

08-12-2011

Cellzome announced that Dr. Gitte Neubauer, one of the scientific founders of Cellzome, has received the highly esteemed EU Women Innovators Award. The award recognizes her outstanding contribution in translating academic research into a commercial venture through the foundation of Cellzome. ...

more

Three grants have been awarded this year which demonstrate the broad utility of Cellzome’s unique chemoproteomics platform

07-12-2011

Cellzome announced the award of a grant by the UK government-backed Technology Strategy Board under its Regenerative Medicine Programme: “Tools and Technologies” for a project which will address the need for better characterisation of human stem cells. Cellzome will use its EpisphereTM ...

more

05-10-2011

A study published in Nature by Cellzome and others has identified that a small molecule inhibitor of BET proteins could potentially be used to treat the aggressive and often incurable mixed lineage (MLL-fusion) leukaemia.The molecular association between BET proteins and factors involved in ...

more

16-09-2011

Cellzome announces that it has successfully reached the clinical candidate milestone for a program as well as a lead declaration milestone for a further target (under a separate program) as part of the kinase alliance with GlaxoSmithKline (GSK). The achievement of these milestones triggers ...

more

12-05-2011

Cellzome announced a joint project with Pfizer’s Pain & Sensory Disorders and Regenerative Medicine unit ‘Neusentis’, to characterize epigenetic factors involved in stem cell differentiation using Cellzome’s EpisphereTM technology.The aim of the project is to shed light on the epigenetic ...

more

25-02-2011

Cellzome announced the appointment of four new members to its Scientific Advisory Board (SAB), further extending its scientific network in immunology, epigenetics and proteomics.Joining the team are Professors Ruedi Aebersold; Anne Ferguson-Smith; Jeannie Lee and Diane Mathis. The ...

more

11-02-2011

Cellzome announced today that it has achieved the second milestone in its epigenetics alliance with GlaxoSmithKline. The milestone triggers a payment of an undisclosed amount from GSK and follows only two months after the first milestone was achieved.The strategic collaboration in epigenetics ...

more

Cellzome Scientists Publish First Chemoproteomic Characterization of HDAC Inhibitors in Nature Biotechnology

25-01-2011

Results of the first ever chemo­proteomic study of inhibition of HDAC (Histone Deacetylase) complexes published in opens up the potential for a new way of studying potency and selectivity for inhibitors of epigenetic drug targets, such as HDACs. In the study, scientists from Cellzome have ...

more

Kinobeads(TM) Technology to Identify a New Generation of Drug

15-09-2008

Cellzome Inc. and GlaxoSmithKline announced the signing of a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases. The alliance gives GSK access to Cellzome's significant expertise in identifying and developing ...

more

15-03-2007

Cellzome Inc. announced that it has received the first milestone payment for its Gamma Secretase Modulator (GSM) program in connection with the selection of a lead compound by Ortho-McNeil Pharmaceutical, Inc. under its agreement with Cellzome. Ortho-McNeil entered into a collaboration and ...

more